Induction of indefinite cardiac allograft survival correlates with toll-like receptor 2 and 4 downregulation after serine protease inhibitor-1 (Serp-1) treatment

Transplantation

Volumn 84, Issue 9, 2007, Pages 1158-1167

  Jiang, Jifu ^a   Arp, Jacqueline ^a   Kubelik, Dalibor ^b   Zassoko, Roman ^b   Liu, Weihua ^b   Wise, Yishai ^b   MacAulay, Colin ^c   Garcia, Bertha ^b   McFadden, Grant ^a,b,c,d,e   Lucas, Alexandra R ^a,b,c,d,e   Wang, Hao ^a,b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Viron Therapeutics Inc   (Canada)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Acute rejection; Innate immunity; Serp 1; Serpin; Toll like receptor; Transplantation; Virus

Indexed keywords

CYCLOSPORIN A; MYELOID DIFFERENTIATION FACTOR 88; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CELL INFILTRATION; CELL MATURATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HETEROTOPIC TRANSPLANTATION; HISTOLOGY; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; TREATMENT OUTCOME;

ANIMALS; CYCLOSPORINE; DOWN-REGULATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MODELS, ANIMAL; RATS; RATS, INBRED BN; SERPINS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRANSPLANTATION, HOMOLOGOUS;

EID: 36249023785     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000286099.50532.b0     Document Type: Article

References (86)

1. Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089.
2. Loucaidou M, Stitchbury J, Lee J, et al. Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression. Transplant Proc 2005; 37: 1760.
3. Delgado JF, Sanchez V, de la Calzada CS. Acute rejection after heart transplantation. Expert Opin Pharmacother 2006; 7: 1139.
4. Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study. Health Technol Assess 2005; 9: 1.
5. Cotts WG, Johnson MR. The challenge of rejection and cardiac allograft vasculopathy. Heart Fail Rev 2001; 6: 227.
6. Schmeding M, Dankof A, Krenn V, et al. C4d in acute rejection after liver transplantation - a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006; 6: 523.
7. Land WG. Immunosuppressive strategies in organ transplantation in the light of innate immunity. Exp Clin Transplant 2006; 4: 406.
8. Uehara S, Chase CM, Colvin RB, et al. Further evidence that NK cells may contribute to the development of cardiac allograft vasculopathy. Transplant Proc 2005; 37: 70.
9. Andrade CF, Waddell TK, Keshavjee S, Liu M. Innate immunity and organ transplantation: The potential role of toll-like receptors. Am J Transplant 2005; 5: 969.
10. Goldstein DR. Toll-like receptors and other links between innate and acquired alloimmunity. Curr Opin Immunol 2004; 16: 538.
11. Takeda K, Akira S. Roles of Toll-like receptors in innate immune responses. Genes Cells 2001; 6: 733.
12. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168: 628.
13. He H, Stone JR, Perkins DL. Analysis of robust innate immune response after transplantation in the absence of adaptive immunity. Transplantation 2002; 73: 853.
14. Beg AA. Endogenous ligands of Toll-like receptors: Implications for regulating inflammatory and immune responses. Trends Immunol 2002; 23: 509.
15. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004; 76: 514.
16. Medzhitov R, Janeway CA, Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298.
17. Li M, Carpio DF, Zheng Y, et al. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001; 166: 7128.
18. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111: 1571.
19. Methe H, Zimmer E, Grimm C, et al. Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 2004; 78: 1324.
20. Kim BS, Lim SW, Li C, et al. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Transplantation 2005; 79: 1370.
21. Wu HS, Zhang JX, Wang L, et al. Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice. Hepatobiliary Pancreat Dis Int 2004; 3: 250.
22. Miller LW, Dai E, Nash P, et al. Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation 2000; 101: 1598.
23. Losa Garcia JE, Mateos Rodriguez F, Jimenez Lopez A, et al. Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages. Respir Med 1998; 92: 722.
24. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 2001; 61: 1957.
25. Moray G, Basaran O, Yagmurdur MC, et al. Immunosuppressive therapy and Kaposi's sarcoma after kidney transplantation. Transplant Proc 2004; 36: 168.
26. Kramer BK, Kruger B, Mack M, et al. Steroid withdrawal or steroid avoidance in renal transplant recipients: Focus on tacrolimus-based immunosuppressive regimens. Transplant Proc 2005; 37: 1789.
27. Seron D, Moreso F. Preservation of renal function during maintenance therapy with cyclosporine. Transplant Proc 2004; 36(2 Suppl): 257S.
28. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: A further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247.
29. Lim SW, Li C, Ahn KO, et al. Cyclosporine-induced renal injury induces toll-like receptor and maturation of dendritic cells. Transplantation 2005; 80: 691.
30. Dai E, Guan H, Liu L, et al. Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem 2003; 278: 18563.
31. Viswanathan K, Liu L, Vaziri S, et al. Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways. Thromb Haemost 2006; 95: 499.
32. Lomas DA, Evans DL, Upton C, et al. Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. J Biol Chem 1993; 268: 516.
33. Upton C, Macen JL, Wishart DS, McFadden G. Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology 1990; 179: 618.
34. Nash P, Whitty A, Handwerker J, Macen J, McFadden G. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1 J Biol Chem 1998; 273: 20982.
35. Macen JL, Upton C, Nation N, McFadden G. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 1993; 195: 348.
36. Bot I, von der Thusen JH, Donners MM, et al. Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/-mice. Circ Res 2003; 93: 464.
37. Lucas A, Liu L, Macen J, et al. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation 1996; 94: 2890.
38. Lucas A, Dai E, Liu L, et al. Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis. J Heart Lung Transplant 2000; 19: 1029.
39. Hausen B, Boeke K, Berry GJ, Morris RE. Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts. Transplantation 2001; 72: 364.
40. Dai E, Viswanathan K, Sun YM, et al. Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. J Biol Chem 2006; 281: 8041.
41. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997; 18: 415.
42. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293.
43. Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res 1996; 78: 405.
44. Chang AW, Kuo A, Barnathan ES, Okada SS. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase. Arterioscler Thromb Vasc Biol 1998; 18: 1855.
45. Germer M, Kanse SM, Kirkegaard T, et al. Kinetic analysis of integrin-dependent cell adhesion on vitronectin - the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem 1998; 253: 669.
46. Chavakis T, Kanse SM, Yutzy B, et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91: 2305.
47. Lijnen HR, Van Hoef B, Lupu F, et al. Function of the plasminogen/ plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18: 1035.
48. Falcone DJ, McCaffrey TA, Haimovitz-Friedman A, et al. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem 1993; 268: 11951.
49. Estreicher A, Muhlhauser J, Carpentier JL, et al. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111: 783.
50. Deng G, Curriden SA, Wang S, et al. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1563.
51. Gettins P, Patston PA, Schapira M. Structure and mechanism of action of serpins. Hematol Oncol Clin North Am 1992; 6: 1393.
52. Forsyth KD, Talbot V, Beckman I. Endothelial serpins - protectors of the vasculature? Clin Exp Immunol 1994; 95: 277.
53. Bedard EL, Jiang J, Arp J, et al. Prevention of chronic renal allograft rejection by SERP-1 protein. Transplantation 2006; 81: 908.
54. Olfert ED, Cross BM, McWilliam AA. Responsibility for the care and use of experimental animals. In: Olfert ED, Cross BM, McWilliam AA, ed. Guide to the Care and Use of Experimental Animals (Vol. 1). Ottawa: Association of Universities and Colleges of Canada, 1993.
55. Wang H, Hosiawa KA, Min W, et al. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol 2003; 171: 3823.
56. Wang H, Arp J, Huang X, et al. Distinct subsets of dendritic cells regulate the pattern of acute xenograft rejection and susceptibility to cyclosporine therapy. J Immunol 2006; 176: 3525.
57. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: Coordinated stimulation of innate and adaptive immunity. J Exp Med 2005; 202: 203.
58. Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 947.
59. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004; 21: 733.
60. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987.
61. Tesar BM, Zhang J, Li Q, Goldstein DR. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a toll-like receptor signal adaptor protein. Am J Transplant 2004; 4: 1429.
62. Horng T, Medzhitov R. Drosophila MyD88 is an adapter in the Toll signaling pathway. Proc Natl Acad Sci USA 2001; 98: 12654.
63. Miyaso H, Morimoto Y, Ozaki M, et al. Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells. Dig Dis Sci 2006; 51: 2007.
64. Kast R, Foley K, Focosi D. Doxorubicin cardiomyopathy via TLR-2 stimulation: Potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir. Hematol Oncol 2007; 25: 96.
65. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887.
66. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276: 10229.
67. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005; 5: 2611.
68. Sacks SH, Zhou W. Allograft rejection: Effect of local synthesis of complement. Springer Semin Immunopathol 2005; 27: 332.
69. Tsoulfas G, Takahashi Y, Ganster RW, et al. Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation 2002; 74: 7.
70. Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005; 171: 780.
71. McKay D, Shigeoka A, Rubinstein M, et al. Simultaneous deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch allograft rejection. Eur J Immunol 2006; 36: 1994.
72. Clarke JH, Cha JY, Walsh MD, et al. Melanoma inhibits macrophage activation by suppressing toll-like receptor 4 signaling. J Am Coll Surg 2005; 201: 418.
73. Schmitz F, Mages J, Heit A, et al. Transcriptional activation induced in macrophages by Toll-like receptor (TLR) ligands: From expression profiling to a model of TLR signaling. Eur J Immunol 2004; 34: 2863.
74. Gu JM, Johns A, Morser J, et al. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice. J Cell Physiol 2005; 204: 73.
75. Coleman JL, Benach JL. The urokinase receptor can be induced by Borrelia burgdorferi through receptors of the innate immune system. Infect Immun 2003; 71: 5556.
76. Hemmi H, Akira S. TLR signalling and the function of dendritic cells. Chem Immunol Allergy 2005; 86: 120.
77. Werling D, Hope JC, Howard CJ, Jungi TW. Differential production of cytokines, reactive oxygen and nitrogen by bovine macrophages and dendritic cells stimulated with Toll-like receptor agonists. Immunology 2004; 111: 41.
78. Burzyn D, Rassa JC, Kim D, et al. Toll-like receptor 4-dependent activation of dendritic cells by a retrovirus. J Virol 2004; 78: 576.
79. Lopez CB, Moltedo B, Alexopoulou L, et al. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J Immunol 2004; 173: 6882.
80. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732.
81. Mu HH, Humphreys J, Chan FV, Cole BC. TLR2 and TLR4 differentially regulate B7-1 resulting in distinct cytokine responses to the mycoplasma superantigen MAM as well as to disease induced by Mycoplasma arthritidis. Cell Microbiol 2006; 8: 414.
82. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002; 20: 55.
83. Schellekens H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 2002; 24: 1720.
84. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans- clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002; 3: 349.
85. Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001; 90: 1.
86. Schellekens H. The immunogenicity of biopharmaceuticals. Neurology 2003; 61(9 Suppl 5): S11.